3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Anemia
4
Multiple Myeloma
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
53
Bevacizumab
52
Cyclophosphamide
49
Docetaxel
42
Carboplatin
40
pembrolizumab
37
Paclitaxel
36
Fluorouracil
36
Cisplatin
35
Radiotherapy
31
Oxaliplatin
31
Capecitabine
29
Irinotecan
28
Dexamethasone
27
Leucovorin
25
Cetuximab
25
Nivolumab
24
Doxorubicin
22
Drug Therapy
21
Erlotinib Hydrochloride
20
Pemetrexed
19
durvalumab
18
trametinib
17
fludarabine
16
atezolizumab
16
Trastuzumab
16
Sunitinib
16
Rituximab
16
Prednisone
16
Sorafenib
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms
×
ACE-011
×
Clear all
NCT00931606
2023-09-13
MK-7962-012
Merck Sharp & Dohme LLC
Phase 2
Terminated
30 enrolled
32 charts